Article Details
Retrieved on: 2025-02-25 15:34:45
Tags for this article:
Click the tags to see associated articles and topics
Summary
The biotech company Elixirgen Therapeutics reports initial success with a novel treatment, EXG-34217, for telomere biology disorders like dyskeratosis congenita, highlighting sustained telomere elongation in stem cells without toxic effects.
Article found on: scienceblog.cincinnatichildrens.org
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here